Basimglurant, a new mechanism of action for control of seizures in tuberous sclerosis complex?
Do you or your loved one suffer from epileptic seizures?
Noema Pharma is developing basimglurant, a drug with a new mechanism of action and a potential for treatment of seizures associated with TSC.
Children older than 5 years, adolescents and adults up to 30 years of age may be able to participate in the study, if their seizures associated with TSC are not sufficiently controlled by their current treatment.
The Galene study is currently open for enrollment in the US, Israel, Turkey and Australia. Further sites are opening in the UK, Spain, Italy, Poland and India.
- To learn more about basimglurant, check out the Research Education Webinar at TSC Alliance website or read about it in the Fall 2022 edition of Perspective magazine.
- For further information, visit clinicaltrials.gov and enter NCT number NCT05059327.
- To find out more about Noema Pharma, visit http://www.noemapharma.com
Are you interested in finding out more? Please contact Ashley Pounders, Director, Medical Affairs at the TSC Alliance, email@example.com